Xenetic Biosciences (XBIO) Stock Forecast, Price Target & Predictions
XBIO Stock Forecast
Xenetic Biosciences stock forecast is as follows:
Xenetic Biosciences Financial Forecast
Xenetic Biosciences Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $611.17K | $651.00K | $605.84K | $486.97K | $414.25K | - | $388.99K | $332.60K | $349.27K | $287.60K | $191.22K | $151.33K | $115.93K | $112.93K | $56.75K | $85.00K |
| Avg Forecast | $230.00K | $750.00K | $540.00K | $510.00K | $670.00K | $460.00K | $440.00K | $610.00K | $490.00K | $410.00K | $420.00K | $390.00K | $100.00K | $200.00K | $290.00K | $60.00K | $129.50K | $127.00K | $60.00K | $110.51K | $6.63K |
| High Forecast | $230.00K | $750.00K | $540.00K | $510.00K | $670.00K | $460.00K | $440.00K | $610.00K | $490.00K | $410.00K | $420.00K | $390.00K | $100.00K | $200.00K | $290.00K | $60.00K | $129.50K | $127.00K | $60.00K | $132.61K | $7.96K |
| Low Forecast | $230.00K | $750.00K | $540.00K | $510.00K | $670.00K | $460.00K | $440.00K | $610.00K | $490.00K | $410.00K | $420.00K | $390.00K | $100.00K | $200.00K | $290.00K | $60.00K | $129.50K | $127.00K | $60.00K | $88.41K | $5.31K |
| # Analysts | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | 11 | 7 | 13 | 13 | 7 | 7 | 14 | 12 |
| Surprise % | - | - | - | - | - | 1.33% | 1.48% | 0.99% | 0.99% | 1.01% | - | 1.00% | 3.33% | 1.75% | 0.99% | 3.19% | 1.17% | 0.91% | 1.88% | 0.51% | 12.81% |
Xenetic Biosciences's average Quarter revenue forecast for Dec 23 based on 1 analysts is $670.00K, with a low forecast of $670.00K, and a high forecast of $670.00K. XBIO's average Quarter revenue forecast represents a 9.63% increase compared to the company's last Quarter revenue of $611.17K (Sep 23).
Xenetic Biosciences EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | 11 | 7 | 13 | 13 | 7 | 7 | 14 | 12 |
| EBITDA | - | - | - | - | - | $-1.15M | $-1.20M | $-915.17K | $-1.56M | $-839.83K | - | $-1.61M | $-1.86M | $-1.37M | $-1.12M | $-1.36M | $-1.21M | $7.99M | $-975.35K | $-1.22M | $-2.24M |
| Avg Forecast | $-138.00K | $-450.00K | $-324.00K | $-306.00K | $-402.00K | $-276.00K | $-264.00K | $-366.00K | $-294.00K | $-1.35M | $-252.00K | $-1.01M | $-20.00K | $-1.23M | $-1.30M | $-1.13M | $-25.90K | $-25.40K | $-1.25M | $-1.57M | $-23.42M |
| High Forecast | $-138.00K | $-450.00K | $-324.00K | $-306.00K | $-402.00K | $-276.00K | $-264.00K | $-366.00K | $-294.00K | $-1.08M | $-252.00K | $-811.29K | $-20.00K | $-984.01K | $-1.04M | $-905.41K | $-25.90K | $-25.40K | $-998.16K | $-1.25M | $-18.74M |
| Low Forecast | $-138.00K | $-450.00K | $-324.00K | $-306.00K | $-402.00K | $-276.00K | $-264.00K | $-366.00K | $-294.00K | $-1.62M | $-252.00K | $-1.22M | $-20.00K | $-1.48M | $-1.56M | $-1.36M | $-25.90K | $-25.40K | $-1.50M | $-1.88M | $-28.11M |
| Surprise % | - | - | - | - | - | 4.15% | 4.54% | 2.50% | 5.32% | 0.62% | - | 1.59% | 93.24% | 1.11% | 0.86% | 1.20% | 46.80% | -314.51% | 0.78% | 0.78% | 0.10% |
13 analysts predict XBIO's average Quarter EBITDA for Dec 20 to be $-25.90K, with a high of $-25.90K and a low of $-25.90K. This is -100.32% lower than Xenetic Biosciences's previous annual EBITDA (Sep 20) of $7.99M.
Xenetic Biosciences Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | 11 | 7 | 13 | 13 | 7 | 7 | 14 | 12 |
| Net Income | - | - | - | - | - | $-1.06M | $-1.05M | $-797.93K | $-1.38M | $-760.25K | - | $-1.54M | $-1.81M | $-1.33M | $-1.09M | $-1.32M | $-1.20M | $-7.56M | $-924.83K | $-1.13M | $-2.27M |
| Avg Forecast | $-308.16K | $-215.71K | $-1.28M | $-1.20M | $-1.17M | $-1.73M | $-1.74M | $-862.85K | $-1.54M | $-1.36M | $-2.93M | $-1.01M | $-2.30M | $-1.24M | $-1.31M | $-1.14M | $-3.07M | $-10.19M | $-1.26M | $-1.58M | $-23.48M |
| High Forecast | $-308.16K | $-215.71K | $-1.28M | $-1.20M | $-1.17M | $-1.73M | $-1.74M | $-862.85K | $-1.54M | $-1.09M | $-2.93M | $-811.29K | $-2.30M | $-990.64K | $-1.05M | $-911.10K | $-3.07M | $-10.19M | $-1.01M | $-1.26M | $-18.78M |
| Low Forecast | $-308.16K | $-215.71K | $-1.28M | $-1.20M | $-1.17M | $-1.73M | $-1.74M | $-862.85K | $-1.54M | $-1.63M | $-2.93M | $-1.22M | $-2.30M | $-1.49M | $-1.58M | $-1.37M | $-3.07M | $-10.19M | $-1.51M | $-1.89M | $-28.18M |
| Surprise % | - | - | - | - | - | 0.61% | 0.60% | 0.92% | 0.90% | 0.56% | - | 1.52% | 0.79% | 1.07% | 0.83% | 1.16% | 0.39% | 0.74% | 0.74% | 0.71% | 0.10% |
Xenetic Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. XBIO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Xenetic Biosciences SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | 11 | 7 | 13 | 13 | 7 | 7 | 14 | 12 |
| SG&A | - | - | - | - | - | $737.24K | $945.95K | $925.74K | $857.17K | $863.23K | - | $907.31K | $977.58K | $945.12K | $890.70K | $930.58K | $880.56K | $804.15K | $787.49K | $927.88K | $1.34M |
| Avg Forecast | $13.42M | $43.77M | $31.51M | $29.76M | $39.10M | $26.84M | $25.68M | $35.60M | $28.59M | $23.93M | $24.51M | $22.73M | $5.83M | $11.66M | $16.90M | $3.50M | $7.55M | $7.40M | $3.50M | $6.44M | $386.60K |
| High Forecast | $13.42M | $43.77M | $31.51M | $29.76M | $39.10M | $26.84M | $25.68M | $35.60M | $28.59M | $23.93M | $24.51M | $22.73M | $5.83M | $11.66M | $16.90M | $3.50M | $7.55M | $7.40M | $3.50M | $7.73M | $463.87K |
| Low Forecast | $13.42M | $43.77M | $31.51M | $29.76M | $39.10M | $26.84M | $25.68M | $35.60M | $28.59M | $23.93M | $24.51M | $22.73M | $5.83M | $11.66M | $16.90M | $3.50M | $7.55M | $7.40M | $3.50M | $5.15M | $309.21K |
| Surprise % | - | - | - | - | - | 0.03% | 0.04% | 0.03% | 0.03% | 0.04% | - | 0.04% | 0.17% | 0.08% | 0.05% | 0.27% | 0.12% | 0.11% | 0.23% | 0.14% | 3.48% |
Xenetic Biosciences's average Quarter SG&A projection for Dec 23 is $39.10M, based on 1 Wall Street analysts, with a range of $39.10M to $39.10M. The forecast indicates a 5203.32% rise compared to XBIO last annual SG&A of $737.24K (Sep 23).
Xenetic Biosciences EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | 11 | 7 | 13 | 13 | 7 | 7 | 14 | 12 |
| EPS | - | - | - | - | - | $-0.69 | $-0.69 | $-0.53 | $-0.10 | $-0.05 | - | $-0.11 | $-0.18 | $-0.13 | $-0.12 | $-0.15 | $-0.14 | $-1.20 | $-0.15 | $-0.18 | $-3.13 |
| Avg Forecast | $-0.20 | $-0.14 | $-0.83 | $-0.78 | $-0.76 | $-1.12 | $-1.13 | $-0.56 | $-1.00 | $-0.60 | $-1.90 | $-1.20 | $-1.50 | $-1.20 | $-1.30 | $-1.30 | $-2.00 | $-6.65 | $-2.20 | $-3.70 | $-2.39 |
| High Forecast | $-0.20 | $-0.14 | $-0.83 | $-0.78 | $-0.76 | $-1.12 | $-1.13 | $-0.56 | $-1.00 | $-0.60 | $-1.90 | $-1.20 | $-1.50 | $-1.20 | $-1.30 | $-1.30 | $-2.00 | $-6.65 | $-2.20 | $-3.70 | $-1.92 |
| Low Forecast | $-0.20 | $-0.14 | $-0.83 | $-0.78 | $-0.76 | $-1.12 | $-1.13 | $-0.56 | $-1.00 | $-0.60 | $-1.90 | $-1.20 | $-1.50 | $-1.20 | $-1.30 | $-1.30 | $-2.00 | $-6.65 | $-2.20 | $-3.70 | $-2.87 |
| Surprise % | - | - | - | - | - | 0.62% | 0.61% | 0.95% | 0.10% | 0.09% | - | 0.09% | 0.12% | 0.11% | 0.09% | 0.12% | 0.07% | 0.18% | 0.07% | 0.05% | 1.31% |
According to undefined Wall Street analysts, Xenetic Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to XBIO previous annual EPS of $NaN (undefined).
Xenetic Biosciences Peer Comparison by Price Target
XBIO Forecast FAQ
What are Xenetic Biosciences's analysts' financial forecasts?
XBIO's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.03M (high $2.03M, low $2.03M), average EBITDA is $-1.218M (high $-1.218M, low $-1.218M), average net income is $-3.005M (high $-3.005M, low $-3.005M), average SG&A $118.46M (high $118.46M, low $118.46M), and average EPS is $-1.95 (high $-1.95, low $-1.95).
Did the XBIO's actual financial results beat the analysts' financial forecasts?
Based on Xenetic Biosciences's last annual report (Dec 2023), the company's revenue was $2.54M, beating the average analysts forecast of $2.18M by 16.51%. Apple's EBITDA was $-4.516M, beating the average prediction of $-1.308M by 245.24%. The company's net income was $-4.135M, missing the average estimation of $-5.501M by -24.83%. Apple's SG&A was $3.56M, missing the average forecast of $127.22M by -97.20%. Lastly, the company's EPS was $-2.71, missing the average prediction of $-3.57 by -24.09%. In terms of the last quarterly report (Sep 2023), Xenetic Biosciences's revenue was $611.17K, beating the average analysts' forecast of $460K by 32.86%. The company's EBITDA was $-1.147M, beating the average prediction of $-276K by 315.47%. Xenetic Biosciences's net income was $-1.056M, missing the average estimation of $-1.726M by -38.83%. The company's SG&A was $737.24K, missing the average forecast of $26.84M by -97.25%. Lastly, the company's EPS was $-0.69, missing the average prediction of $-1.12 by -38.39%